Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International AB has initiated a Phase 2a clinical trial for its drug candidate BI-1206, in combination with pembrolizumab, targeting advanced or metastatic non-small cell lung cancer (NSCLC) and uveal melanoma. This trial follows promising results from Phase 1, where BI-1206 demonstrated safety and clinical activity, offering hope for overcoming resistance mechanisms in cancer treatment and potentially expanding its use across various indications where pembrolizumab is approved.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a clinical-stage biotech company focused on discovering and developing novel, first-in-class antibodies for cancer immunotherapy. The company operates ongoing clinical programs in Phase 1/2 trials targeting hematological cancers and solid tumors, utilizing its proprietary F.I.R.S.T™ technology platform to identify promising new drug candidates.
Average Trading Volume: 83,872
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.86B
See more data about BINV stock on TipRanks’ Stock Analysis page.